Acceleron to Webcast Fourth Quarter and Full Year 2019 Operating and Financial Results on February 27, 2020
18 Febrero 2020 - 6:00AM
Business Wire
Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host
a webcast and conference call on Thursday, February 27, 2020 at
5:00 p.m. EST to discuss its fourth quarter and full year 2019
operating and financial results.
The webcast will be accessible under "Events &
Presentations" in the Investors & Media page of the company's
website at www.acceleronpharma.com. Individuals can participate in
the conference call by dialing 877-312-5848 (domestic) or
253-237-1155 (international) and refer to the “Acceleron Fourth
Quarter and Full Year 2019 Earnings Call.”
The archived webcast will be available for replay on the
Acceleron website approximately two hours after the event.
About Acceleron
Acceleron is a biopharmaceutical company dedicated to the
discovery, development, and commercialization of therapeutics to
treat serious and rare diseases. Acceleron’s leadership in the
understanding of TGF-beta superfamily biology and protein
engineering generates innovative compounds that engage the body's
ability to regulate cellular growth and repair.
Acceleron focuses its research and development efforts in
hematologic, pulmonary, and neuromuscular diseases. In hematology,
Acceleron and its global collaboration partner, Bristol-Myers
Squibb, are co-promoting newly approved REBLOZYL®
(luspatercept-aamt), the first and only approved erythroid
maturation agent, in the United States and are developing
luspatercept for the treatment of chronic anemia in myelodysplastic
syndromes and myelofibrosis. Acceleron is developing sotatercept
for the treatment of pulmonary arterial hypertension, having
recently reported positive topline results of the Phase 2 PULSAR
trial and actively enrolling patients in the Phase 2 SPECTRA trial.
The company is also advancing its neuromuscular program with
ACE-083, a locally-acting Myostatin+ agent in Phase 2 development
in Charcot-Marie-Tooth disease.
For more information, please visit www.acceleronpharma.com.
Follow Acceleron on Social Media: @AcceleronPharma and
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200218005187/en/
Acceleron Pharma Inc. Investors: Todd James, (617) 649-9393
Senior Vice President, Corporate Affairs and Investor Relations or
Media: Matt Fearer, (617) 301-9557 Director, Corporate
Communications
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024
Real-Time news about Acceleron Pharma Inc (NASDAQ): 0 recent articles
Más de Acceleron Pharma Inc. Artículos de Noticias